

Remarks

Claims 1-7, 12, 14, 15, 17, 18 and 20-28 are pending in the application. Claims 1-7, 12, 14, 15, 17, and 23-27 are allowed. Claims 18, 20-22 and 28 are rejected under 35 U.S.C. 112, first paragraph. Reconsideration is respectfully requested in view of the above changes and the following remarks.

Typographical errors have been corrected in claims 2 and 24. Claim 23 has been amended to make the representation of the sulfone group in formula VI consistent with the representation of the same group in other claims. Punctuation has been added in claims 3 and 25.


Examiner alleges that the specification does not enable a person skilled in the art to practice the claimed invention with respect to all "cancer" and all "other proliferative disorders". The rejection however indicates that applicants have enabled the practice of the invention for treating breast and prostate tumors, and small cell lung and colorectal carcinomas.

Without acquiescing in the rejection, and in an effort to advance prosecution, claim 18 has been rewritten to recite a method for treating breast, prostate, non-small cell lung and colorectal cancer. The claim now reflects treatment of the disorders which Examiner agrees are supported and enabled by the specification.

All claims remaining in the application are believed in condition for allowance. An early action toward that end is earnestly solicited.

Respectfully submitted,

STEPHEN C. COSENZA, *et al.*

By: 

DANIEL A. MONACO

Registration No. 30,480

Drinker Biddle & Reath, LLP

One Logan Square

18th and Cherry Streets

Philadelphia, PA 19103-6996

(215) 988-3312

(215) 988-2757 - Fax

Attorney for the Applicants